Ascentage Pharma Group International reported earnings results for the full year ended December 31, 2025. For the full year, the company reported sales was CNY 574.12 million compared to CNY 980.65 million a year ago. Net loss was CNY 1,242.77 million compared to CNY 405.43 million a year ago.

Basic loss per share from continuing operations was CNY 3.49 compared to CNY 1.34 a year ago.